WEKO3
アイテム
マーモセットの deprenyl による部分的神経保護作用とパーキンソニズムに対する明らかな軽減効果
https://repo.qst.go.jp/records/61343
https://repo.qst.go.jp/records/613430c1e108b-abcd-4f1c-a859-7a4643d1e8ac
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2006-05-24 | |||||
| タイトル | ||||||
| タイトル | マーモセットの deprenyl による部分的神経保護作用とパーキンソニズムに対する明らかな軽減効果 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
安東, 潔
× 安東, 潔× 稲次, 基希× 前田, 純× 羽田, 栄輔× 樋口, 真人× 須原, 哲也× 石井, 一× 谷岡, 功邦× 安東 潔× 稲次 基希× 前田 純× 羽田 栄輔× 樋口 真人× 須原 哲也 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The neurobehavioral protection of single dose deprenyl against MPTP toxicity was studied in common marmosets by behavioral observations and ARG (autoradiography). Marmosets in the control group received MPTP at 2 mg/kg, s.c. for 3 consecutive days while marmosets in the deprenyl pretreatment group received the same MPTP administration regimen but intragastric administration of deprenyl at 10 mg/kg before the first MPTP administration. As a result, marked degeneration of dopamine neurons at the striatum was observed in the control group in ARG using [11C]PE2I, a tracer for dopamine transporters. In the deprenyl group, the binding of [11C]PE2I was significantly higher than that of the control group but still lower at the degree of 20% of the binding of the brains of MPTP-free marmosets. On the other hand, clear sensitivity changes were not observed at dopamine D1 and D2 receptors in the striatum as observed no clear changes of binding potential of [11C]SCH-23390 and [11C] raclopride. In result of behavioral observation performed before ARG, the animals in the control group consistently showed clear parkinsonism including tremor, immobility, etc while marked attenuation of parkinsonism was observed in the deprenyl group. In conclusion, MPTP administration regimen used in this study is appropriate for enough dopamine neuroterminal damage for clear and long lasting manifestation of parkinsonism. Marked behavioral protection by deprenyl was considered to be related other mechanism than mere dopamine neurodegeneration at the striatum. MPTP-induced degeneration of dopamine neuron protected by deprenyl partially but marked recovery from parkinsonism in common marmosets Marmosets in the deprenyl pretreatment group received the same MPTP treatment as in the control group and also received an intragastric administration of deprenyl at 10 mg/kg 2 hrs before the first MPTP administration (n=5 for each group). On the other hand, the animals in the deprenyl group showed less degree of the signs and showed a temporal decrease of activity counts and then recovered to the level of pre-MPTP period in a week while the binding of the animal putamen in the deprenyl group went down to 25.2% of the level. In the present study, the protective action of deprenyl was demonstrated in its single dose. The mechanism of behavioral protection may be related to the irreversible MAO-B inhibition of deprenyl in the nigrostriatal dopamine neurons. In spite of clear behavioral recovery from parkinsonian signs, the dopaminergic neural protection by deprenyl was partial. Therefore, other neural systems than the dopamine system may contribute for the behavioral recovery in the present deprenyl protection. Regardless of the underlying mechanism not known at the moment, the present preclinical test method may prove to be sensitive for detecting neuroprotective effects of drugs for the treatment of Parkinson's disease. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第79回日本薬理学会年会 | |||||
| 発表年月日 | ||||||
| 日付 | 2005-03-09 | |||||
| 日付タイプ | Issued | |||||
